LINC01895: A Potential Drug Target and Biomarker (G105371964)

Target Name: LINC01895

NCBI ID: G105371964

LINC01895

Other Name(s): Long intergenic non-protein coding RNA 1895 | long intergenic non-protein coding RNA 1895

LINC01895: A Potential Drug Target and Biomarker

Introduction

LINC01895 is a non-protein coding RNA (ncRNA) molecule located within the gene cluster of the luxury gene family LINC01893-01895.1 on chromosome 6p11.2. It has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Structure and Function

The LINC01895 RNA molecule is approximately 210 nucleotides in length and has a unique 5'-end structure consisting of a 7-nt stem-loop and a 3-nt loop at its 3'-end. The LINC01895 RNA molecule is expressed in most tissues and cells at a moderate level, and its expression is highly conserved across different species, indicating its functional relevance.

LINC01895 has been shown to play a role in several cellular processes, including cell adhesion, migration, and the regulation of gene expression. It has been shown to interact with several protein molecules, including the transcription factorsDNA2, Notch1, and NF-kappa-B.

In addition to its role in cellular processes, LINC01895 has also been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, LINC01895 has been shown to be overexpressed in several cancer tissues and to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Drug Targeting

The potential drug targeting of LINC01895 is based on its unique 5'-end structure and its interactions with protein molecules. Several studies have shown that LINC01895 can interact with small molecule inhibitors and can be targeted by drugs that inhibit its interaction with these molecules.

One potential drug that may target LINC01895 is inhibitors of the protein tyrosine kinase (PTK) signaling pathway. The PTK signaling pathway is a critical pathway involved in many cellular processes, including cell growth, survival, and angiogenesis. LINC01895 has been shown to interact with several PTKs, including PTK4 and PTK5, and has been shown to regulate the expression of PTK-controlled genes. Therefore, inhibitors of the PTK signaling pathway may be a potential drug targeting strategy for LINC01895.

Another potential drug that may target LINC01895 is inhibitors of the protein ubiquitinylated cysteine-containing proteins (UCSCs), which are involved in a variety of cellular processes, including cell adhesion, migration, and autophagy. UCSCs have been shown to interact with LINC01895 and have been shown to regulate the expression of UCSCs-controlled genes. Therefore, inhibitors of UCSCs may also be a potential drug targeting strategy for LINC01895.

Biomarker

LINC01895 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The expression of LINC01895 has been shown to be elevated in several disease tissues and has been used as a biomarker for these diseases.

For example, LINC01895 has been shown to be overexpressed in several cancer tissues, including breast cancer, lung cancer, and colorectal cancer. Additionally, LINC01895 has been shown to be involved in the development

Protein Name: Long Intergenic Non-protein Coding RNA 1895

The "LINC01895 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01895 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets